Targeting MAPK4 may offer a new therapeutic opportunity for TNBC
MAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.
Read moreMAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.
Read moreThe findings suggest that therapies that interfere with MAPK6 activity may offer an effective cancer treatment approach.
Read moreInhibiting MAPK4 simultaneously inactivated both androgen receptor and AKT and stopped cancer growth in animal models.
Read more